ESPL1 and myelodysplastic syndrome: In order to investigate the potential context between altered separase activity and MDS progression we have comparatively analyzed separase proteolytic activity, karyotype, centrosomal, mutational and clinical status in a total of 67 bone marrow samples derived from 54 patients with MDS, sAML, de novo AML and from 7 corresponding healthy control donors.